Estrogen Patch Shortages Reported Due to Surging Demand for Menopause Treatment
Widespread shortages of estrogen patches are affecting women across the United States after the FDA removed a black-box safety warning on hormone replacement therapies in November 2025, triggering a 26% surge in usage by February 2026 and a 184% increase since 2023. Manufacturers like Sandoz cite unprecedented demand they cannot meet, while CVS Health reports insufficient supply from producers who face limited profit incentives on generic drugs. More than 1 million American women enter menopause annually, and experts warn shortages could persist for three years as building new production facilities takes years. Women like 50-year-old Amy Satterlund are forced to search multiple pharmacies or switch medications, risking symptom relapse or new side effects.
FDA Policy Change and Surge in Hormone Therapy Demand
▪Use of estrogen patches jumped 26% by the end of February 2026 according to Truveta health analytics data.
▪Use of vaginal creams for hormone replacement therapy rose 122% since 2023.
▪The U.S. Food and Drug Administration removed a long-standing black-box safety warning on hormone replacement therapies in November 2025.
▪More than 1 million women in the U.S. enter menopause every year.
▪Estrogen patch use increased 184% since 2023.
Supply Chain Challenges and Production Constraints
▪Dr. Gillian Goddard stated that for 20 years less than 5% of women took hormone therapy.
▪Estrogen patches are generic drugs with lower profit margins, creating less incentive for drug makers to invest in production.
▪Building new pharmaceutical production facilities can take years.
▪Sandoz stated that the FDA's removal of the safety warning in November created unprecedented demand that cannot fully be met at present.
▪Shortages of estrogen patches could last as long as three years according to experts.
▪CVS Health reported that manufacturers have not been able to supply enough estrogen patch product in recent weeks.
Patient Impact and Clinical Concerns
▪Stopping hormone replacement therapy treatment abruptly can cause menopause symptoms to return according to doctors.
▪Amy Satterlund, a 50-year-old patient, has used the estrogen patch for about 18 months and is now struggling to find it.
▪Women are searching multiple pharmacies or switching medications due to estrogen patch shortages.
▪Switching hormone replacement therapy products may lead to new side effects entirely according to doctors.
▪Menopause symptoms that hormone replacement therapy treats include hot flashes, mood changes, and sleep problems.
Perspective of Pharmaceutical manufacturers (Sandoz and others)
▪Low profit margins on generic estrogen patches make it economically challenging for manufacturers to rapidly scale production capacity.
Perspective of Women experiencing menopause and their doctors
▪Women seeking estrogen patches face the choice between enduring menopause symptoms or accepting potentially problematic medication switches.
▪The estrogen patch shortage represents a failure to meet the healthcare needs of over 1 million women entering menopause annually in the United States.
Perspective of U.S. Food and Drug Administration
▪The FDA's November 2025 removal of the black-box warning on hormone replacement therapies was intended to reduce barriers to menopause treatment.
Story comments
Loading comments…